Literature DB >> 15923275

Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family.

S McVety, L Li, P H Gordon, G Chong, W D Foulkes.   

Abstract

BACKGROUND: A 3 bp deletion located at the 5' end of exon 3 of MLH1, resulting in deletion of exon 3 from RNA, was recently identified. HYPOTHESIS: That this mutation disrupts an exon splicing enhancer (ESE) because it occurs in a purine-rich sequence previously identified as an ESE in other genes, and ESEs are often found in exons with splice signals that deviate from the consensus signals, as does the 3' splice signal in exon 3 of MLH1.
DESIGN: The 3 bp deletion and several other mutations were created by polymerase chain reaction mutagenesis and tested using an in vitro splicing assay. Both mutant and wild type exon 3 sequences were cloned into an exon trapping vector and transiently expressed in Cos-1 cells.
RESULTS: Analysis of the RNA indicates that the 3 bp deletion c.213_215delAGA (gi:28559089, NM_000249.2), a silent mutation c.216T-->C, a missense mutation c.214G-->C, and a nonsense mutation c.214G-->T all cause varying degrees of exon skipping, suggesting the presence of an ESE at the 5' end of exon 3. These mutations are situated in a GAAGAT sequence 3 bp downstream from the start of exon 3.
CONCLUSIONS: The results of the splicing assay suggest that inclusion of exon 3 in the mRNA is ESE dependent. The exon 3 ESE is not recognised by all available motif scoring matrices, highlighting the importance of RNA analysis in the detection of ESE disrupting mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15923275      PMCID: PMC2564635          DOI: 10.1136/jmg.2005.031997

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  28 in total

1.  A nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families.

Authors:  A Stella; A Wagner; K Shito; S M Lipkin; P Watson; G Guanti; H T Lynch; R Fodde; B Liu
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 2.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

3.  Predictive identification of exonic splicing enhancers in human genes.

Authors:  William G Fairbrother; Ru-Fang Yeh; Phillip A Sharp; Christopher B Burge
Journal:  Science       Date:  2002-07-11       Impact factor: 47.728

Review 4.  NASty effects on fibrillin pre-mRNA splicing: another case of ESE does it, but proposals for translation-dependent splice site choice live on.

Authors:  Lynne E Maquat
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

5.  Description and functional analysis of a novel in frame mutation linked to hereditary non-polyposis colorectal cancer.

Authors:  T E Raevaara; T Timoharju; K E Lönnqvist; R Kariola; M Steinhoff; R M W Hofstra; E Mangold; Y J Vos; M Nyström-Lahti
Journal:  J Med Genet       Date:  2002-10       Impact factor: 6.318

6.  A nonsense mutation in the fibrillin-1 gene of a Marfan syndrome patient induces NMD and disrupts an exonic splicing enhancer.

Authors:  Massimo Caputi; Raymond J Kendzior; Karen L Beemon
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

7.  Alternatively spliced TCR mRNA induced by disruption of reading frame.

Authors:  Jun Wang; John I Hamilton; Mark S Carter; Shulin Li; Miles F Wilkinson
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

8.  Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function.

Authors:  Barbara Quaresima; Pietro Alifano; Pierfrancesco Tassone; Enrico V Avvedimento; Francesco S Costanzo; Salvatore Venuta
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

9.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.

Authors:  Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde
Journal:  Am J Hum Genet       Date:  2003-03-25       Impact factor: 11.025

10.  Selection of alternative 5' splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1.

Authors:  I C Eperon; O V Makarova; A Mayeda; S H Munroe; J F Cáceres; D G Hayward; A R Krainer
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

View more
  15 in total

1.  A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.

Authors:  A Joseph Bloom; Oscar Harari; Maribel Martinez; Xiaochun Zhang; Sandra A McDonald; Sharon E Murphy; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

2.  Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.

Authors:  Yoshihisa Kobayashi; Chhayheng Chhoeu; Jiaqi Li; Kristin S Price; Lesli A Kiedrowski; Jamie L Hutchins; Aaron I Hardin; Zihan Wei; Fangxin Hong; Magda Bahcall; Prafulla C Gokhale; Pasi A Jänne
Journal:  Nature       Date:  2022-03-02       Impact factor: 49.962

3.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

4.  Genomic features defining exonic variants that modulate splicing.

Authors:  Adam Woolfe; James C Mullikin; Laura Elnitski
Journal:  Genome Biol       Date:  2010-02-16       Impact factor: 13.583

5.  Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics.

Authors:  Sven Arnold; Daniel D Buchanan; Melissa Barker; Lesley Jaskowski; Michael D Walsh; Genevieve Birney; Michael O Woods; John L Hopper; Mark A Jenkins; Melissa A Brown; Sean V Tavtigian; David E Goldgar; Joanne P Young; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2009-05       Impact factor: 4.878

6.  Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors.

Authors:  P T Campbell; K Curtin; C M Ulrich; W S Samowitz; J Bigler; C M Velicer; B Caan; J D Potter; M L Slattery
Journal:  Gut       Date:  2008-06-03       Impact factor: 23.059

7.  Transposable elements in disease-associated cryptic exons.

Authors:  Igor Vorechovsky
Journal:  Hum Genet       Date:  2009-10-10       Impact factor: 4.132

8.  The exon 29 c.3535A>T in the alpha-2-macroglobulin gene causing aberrant splice variants is associated with mastitis in dairy cattle.

Authors:  Xiuge Wang; Jinming Huang; Lihong Zhao; Changfa Wang; Zhihua Ju; Qiuling Li; Chao Qi; Yan Zhang; Zebin Zhang; Wei Zhang; Minghai Hou; Jinduo Yuan; Jifeng Zhong
Journal:  Immunogenetics       Date:  2012-08-26       Impact factor: 2.846

9.  The deep intronic c.903+469T>C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria.

Authors:  Katerina Homolova; Petra Zavadakova; Thomas Koed Doktor; Lisbeth Dahl Schroeder; Viktor Kozich; Brage S Andresen
Journal:  Hum Mutat       Date:  2010-04       Impact factor: 4.878

10.  The MLH1 2101C>A (Q701K) variant increases the risk of gastric cancer in Chinese males.

Authors:  Wenxian Zhi; Binshuang Xue; Lifeng Wang; Nong Xiao; Qiong He; Yaping Wang; Yimei Fan
Journal:  BMC Gastroenterol       Date:  2011-12-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.